Российские данные международного регистра ENDORSE по выявлению больных с риском тромбоза глубоких вен, госпитализированных в стационары, располагающие возможностями оказания экстренной медицинской помощи
Сулимов В.А., Беленцов С.М., Головина Н.И., Дубровная Н.П., Жидков К.П., Елисеева К.В., Казанчан П.О., Редькин А.В., Родоман Г.В., Фридман И.Л., Шершнев В.Н. Российские данные международного регистра ENDORSE по выявлению больных с риском тромбоза глубоких вен, госпитализированных в стационары, располагающие возможностями оказания экстренной медицинской помощи. Consilium Medicum. 2008; 10 (8): 122–128.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Schellong SM, Bounameaux H, Buller H. Venous Thromboembolism. In The ESC Textbook of Cardiovascular Medicine. Ed: Camm AJ, Luscher ThF, Serruys PW. Blackwell Publishing 2006; p. 1067–92.
2. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest 2001; 119: 132S–175S.
3. Samama MM et al. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415–20.
4. International Multicenter Trial. Prevention of fatal pulmonary embolism by low doses of heparin. Lancet 1975; 2: 45–51.
5. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222–331.
6. Аnderson FA, Wheeler HB, Goldberg RJ et al. A population-based perspective of hospital incidence and case-fatality rates of deep venous thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 1991; 151: 933–8.
7. Cohen AT. Venous thromboembolic disease management in of non-surgical moderate and high-risk patients. Semin Hematol 2002; 28 (suppl.): 51–5.
8. Eriksson BI, Lassen MR. The PENTassccharide in Hip-FRActure Surgery Plus (PENTIFRA Plus) Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled double-blind study. Arch Intern Med 2003; 163: 1337–42.
9. Tveit DP, Hypolite IO, Hsheih P at al. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 2002; 39: 1011–7.
10. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis N. Engl. J. Med. 2001; 344: 1222–1331
11. Geerts W et al. Chest, 2004; 126 (Suppl. 3): 338S–400S.
12. Cohen AT, Alikhan R, Arcelius J et al. Venous thromboembolism risk assessment in medical patients (abstract). Blood 2002; 100: 280a.
13. Oger E, Bressollette L, Nonent M et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients: the TADEUS Project. Thromb Haemost 2002; 88: 592–7.
14. Samama M.M., Cohen A, Darmon J et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N. Engl. J. Med. 1999; 341: 793–800.
15. Howell M, Geraci J, Knowlton A, Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective case-report study. J. Clin. Epidemiol. 2001; 54: 810–816.
2. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest 2001; 119: 132S–175S.
3. Samama MM et al. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415–20.
4. International Multicenter Trial. Prevention of fatal pulmonary embolism by low doses of heparin. Lancet 1975; 2: 45–51.
5. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222–331.
6. Аnderson FA, Wheeler HB, Goldberg RJ et al. A population-based perspective of hospital incidence and case-fatality rates of deep venous thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 1991; 151: 933–8.
7. Cohen AT. Venous thromboembolic disease management in of non-surgical moderate and high-risk patients. Semin Hematol 2002; 28 (suppl.): 51–5.
8. Eriksson BI, Lassen MR. The PENTassccharide in Hip-FRActure Surgery Plus (PENTIFRA Plus) Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled double-blind study. Arch Intern Med 2003; 163: 1337–42.
9. Tveit DP, Hypolite IO, Hsheih P at al. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 2002; 39: 1011–7.
10. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis N. Engl. J. Med. 2001; 344: 1222–1331
11. Geerts W et al. Chest, 2004; 126 (Suppl. 3): 338S–400S.
12. Cohen AT, Alikhan R, Arcelius J et al. Venous thromboembolism risk assessment in medical patients (abstract). Blood 2002; 100: 280a.
13. Oger E, Bressollette L, Nonent M et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients: the TADEUS Project. Thromb Haemost 2002; 88: 592–7.
14. Samama M.M., Cohen A, Darmon J et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N. Engl. J. Med. 1999; 341: 793–800.
15. Howell M, Geraci J, Knowlton A, Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective case-report study. J. Clin. Epidemiol. 2001; 54: 810–816.
Авторы
В.А.Сулимов, С.М.Беленцов, Н.И.Головина, Н.П.Дубровная,
К.П.Жидков, К.В.Елисеева, П.О.Казанчан, А.В.Редькин,
Г.В.Родоман, И.Л.Фридман, В.Н.Шершнев
К.П.Жидков, К.В.Елисеева, П.О.Казанчан, А.В.Редькин,
Г.В.Родоман, И.Л.Фридман, В.Н.Шершнев
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.